Phenylketonuria;Phénylcétonurie

Presse Medicale

Volumn 35, Issue 3 II, 2006, Pages 502-508

  Feillet, François ^a  

^a HÔPITAL D ENFANTS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; TETRAHYDROBIOPTERIN; TYROSINE;

CLINICAL FEATURE; DIAGNOSTIC TEST; DIET RESTRICTION; FETUS DEVELOPMENT; GENETIC DISORDER; HUMAN; HYPOPIGMENTATION; INCIDENCE; LABORATORY TEST; MEDICAL INFORMATION; MENTAL DEFICIENCY; NEWBORN SCREENING; PHENYLKETONURIA; PREGNANCY; REVIEW;

EID: 33645292339     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(06)74625-5     Document Type: Article

References (24)

1. Jervis GA. Studies on phenylpyruvic oligophrenia: position of metabolic error. J Biol Chem. 1953; 169: 292-6.
2. Smith I, Lee P. The hyperphenylalaninemias. In: J Fernandes, JM Saudubray, van den Berghe G, editors. Inborn Metabolic Diseases, Diagnosis and treatment. Berlin Heidelberg New York: Springer-Verlag; 2000. p. 171-84.
3. Abadie V, Berthelot J, Feillet F, Maurin N, Mercier A, de Baulny H et al. Neonatal screening and long-term follow-up of phenylketonuria: the French database. Early Hum Dev. 2001; 65: 149-58.
4. Abadie V, Berthelot J, Feillet F, Maurin N, Mercier A, Ogier de Baulny H et al. Consensus national sur la prise en charge des enfants dépistés avec une hyperphénylalaninémie. Arch Ped. 2005; 12: 594-601.
5. Walter JH, White FJ, Hall SK, MacDonald A, Boneh A, Francis DE et al. How practical are recommendations for dietary control in phenylketonuria. Lancet. 2002; 360: 55-7.
6. Phenylalanine Hydroxylase Locus Knowledgebase, 15 août 2005. http://www.pahdb.mcgill.ca/
7. Scriver CR, Hurtubise M, Konecki D, Phommarinh M, Prevost L, Erlandsen H et al. PAHdb 2003: what a locus-specific knowledge-base can do. Hum Mutat. 2003; 21: 333-44.
8. International database of patients and mutations causing BH4-reponsive HPA/PKU, 2005 http://www.bh4.org/biopku.html
9. Lindner M, Haas D, Mayatepek E, Zschocke J, Burgard P. Tetrahydrobiopterin responsiveness in phenylketonuria differs between patients with the same genotype. Mol Genet Metab. 2001; 73: 104-6.
10. Dhondt JL, Hayte JM. Repérage des hyperphénylalaniné mies par déficit en tétrahydrobioptérine. Ann Biol Clin. 2002; 60: 165-71.
11. Krause W, Halminsli M, McDonald L, Dempure P, Salvo R, Friedes SR et al. Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients treated with phenylketonuria. J Clin Invest. 1985; 75: 40-8.
12. Avison MJ, Herschkowitz N, Novotny EJ, Petroff OAC, Rothman DL, Colombo JP et al. Proton NMR observation of phenylalanine and an aromatic metabolite in the rabbit brain in vivo. Pediatr Res. 1990; 27: 566-70.
13. Elsliger MA, Thierault GR, Gauthier D. In vitro localization of the protein synthesis defect associated with experimental phenylketonuria. Neurochem Res. 1989; 14: 81-4.
14. Dyer CA, Kendler A, Philibotte T, Gardiner P, Cruz J, Levy HL. Evidence for central nervous system glial cell plasticity in phenylketonuria. J Neuropathol Exp Neurol. 1996; 55: 795-814.
15. Muntau AC, Röschinger W, Habbich M, Demmelmair H, Hoffmann B, Sommerhoff CP et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. New Eng J Med. 2002; 347: 2122-32.
16. Blau N, Erlandsen H. The metabolic and molecular bases of tetrahydrobiopterin-responive phenylalanine hydroxylase deficiency. Mol Genet Metab. 2004; 82: 101-11.
17. Guttler F, Lou H, Andresen J, Kok K, Mikkelsen I, Nielsen KB et al. Cognitive development in offspring of untreated and preconceptionally treated maternal phenylketonuria. J Inherit Metab Dis. 1990; 13: 665-71.
18. Feillet F, Abadie V, Berthelot J, Maurin N, Ogier de Baulny H, Vidailhet M et al. Maternal phenylketonuria: the French survey. Eur J Pediatr. 2004; 163: 540-6.
19. Koch R, Hanley W, Levy H, Matalon K, Matalon R, Rouse B et al. The maternal phenylketonuria international study: 1984-2002. Pediatrics. 2003; 112: 1523-9.
20. Huijbregts SC, de Sonneville LM, Licht R, van Spronsen FJ, Verkerk PH, Vranken M. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia. 2002; 40: 7-15.
21. Weglage J, Wiedermann D, Denecke J, Feldmann R, Koch R, Ullrich K et al. Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann Neurol. 2001; 50: 463-7.
22. Verlinsky Y, Retchitsky S, Verlinsky O, Strom C, Kuliev A. Preimplantation testing for phenylketonuria. Fertil Steril. 2001; 76: 346-9.
23. Sarkissian CN, Shao Z, Blain FR, Peevers R, Su H, Heft R et al. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci USA. 1999; 96: 2339-44.
24. Mochizuki S, Mizukami H, Ogura T, Kure S, Ichinobe A, Kojima K et al. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioural recovery in phenylketonuria mice. Gene Ther. 2004; 11: 1081-6.